Drug Recall: S2 Racepinephrine Inhalation Solution Short Fill
Nephron Sc Inc recalls approximately 925,920 vials of S2 Racepinephrine Inhalation Solution due to short fill. Affected lots may contain less medication than labeled.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II voluntary recall with no reported illnesses or injuries. The hazard is short fill (underfill), which is a quality and dosing issue rather than contamination or direct safety hazard.
Plain-English summary
Nephron Sc Inc has recalled approximately 925,920 vials of S2 Racepinephrine Inhalation Solution, USP 2.25% Bronchodilator in 30 x 0.5 mL Sterile Unit-of-Use vials (NDC 0487-5901-99). The recall applies to Lot numbers 126461 and 126431 with expiration date 04/30/2023.
The recall was initiated due to short fill, meaning the vials contain less medication than the labeled quantity. This is a Class II recall initiated voluntarily by the manufacturer.
The affected vials were distributed nationwide within the United States, including Puerto Rico and Guatemala.
Patients and healthcare providers in possession of these vials should stop using them and contact Nephron Sc Inc for further instructions.
The recalled product
- Product
- S2 (RACEPINEPHRINE HYDROCHLORIDE)
- Brand
- S2
- Manufacturer
- Nephron Sc Inc
- Category
- Drug
- Affected units
- 925,920
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 126461
- 126431 Exp. 04/30/2023
UPCs (1)
- 304875901999
Distribution
Part of a larger recall action
This product is one of 2 recalled by Nephron Sc Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · S2
- ModerateRacepinephrine Inhalation Solution Recalled for Improper Storage Conditions
FDA (Drugs) · 2022-08-17
Same manufacturer · Nephron Sc Inc
See all →- HighSterile Water for Injection Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-03-08
- HighAsthmanefrin Bronchodilator Medication Vials Recalled Nationwide for Short Fill
FDA (Drugs) · 2023-02-01
- HighSodium Chloride Injection Recalled for Manufacturing Control Deviations
FDA (Drugs) · 2023-02-01
- HighSterile water injection vials recalled for trace product carryover risk
FDA (Drugs) · 2023-02-01
- HighInjectable ketorolac tromethamine recalled nationwide for potential cross-contamination
FDA (Drugs) · 2022-08-24
Same hazard · short fill
See all →- HighPrescription respiratory drug recalled for short fill in unit-dose vials
FDA (Drugs) · 2024-05-01
- ModerateFDA Recalls Fentanyl Injection Solution for Underfilled Cassettes
FDA (Drugs) · 2023-02-01
- LowExela Pharma Recalls Potassium Acetate Injection Vials Due to Short Fill
FDA (Drugs) · 2020-09-23
- ModerateAirgas Recalls 145 Compressed Oxygen Cylinders Due to Short Fill Error
FDA (Drugs) · 2014-01-01
Similar recalls
- ModerateNephron Recalls Asthmanefrin Racepinephrine Inhalation Solution Due to Discoloration
FDA (Drugs) · 2015-12-09
- ModerateRacepinephrine Inhalation Solution Recalled for Improper Storage Conditions
FDA (Drugs) · 2022-08-17
- ModerateAsthmanefrin Racephinephrine Inhalation Solution Recalled Due to Improper Storage
FDA (Drugs) · 2022-08-17
- ModerateNephron Recalls Asthmanefrin Inhalation Solution Due to Discoloration
FDA (Drugs) · 2015-12-09
- HighFDA Recalls Norepinephrine Injection Due to Sterility Concerns
FDA (Drugs) · 2023-03-08
- LowNephron Recalls Succinylcholine Chloride Injection Due to Incorrect Labeling
FDA (Drugs) · 2019-11-06